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Introduction
P53 is among the most commonly mutated genes in various can-
cers, but particularly in lung cancer (1, 2). The majority of p53 
mutations found in human cancers, including lung cancers, are 
missense mutations that have “driver” roles (3, 4), suggesting 
a selective advantage for retaining the mutated allele. It is well 
established that loss of WT p53 increases vulnerability to tumor 
formation (5), whereas tumor-derived mutants of p53 show 
gain-of-function (GOF) properties, which confer a selective 
growth advantage to cancer cells. Several mouse models have 
been reported to investigate GOF properties of p53 mutants 
(6–10). In addition to loss of WT p53 function, the ability of 
GOF p53 to activate transcription of proliferative genes (11–13) 
or to deregulate signaling pathways (14) has been connected 
to its oncogenic properties. Inhibition of tumor formation by 
knockdown of endogenous mutant p53 has been demonstrated 
in human lung cancer cells using RNAi and knockin (KI) mouse 
models (15, 16). A recent study has reported that inactivation 
or destabilization of GOF p53 reduces tumor growth in mice, 
extending their survival (17). These observations demonstrate 
a dependence of the tumor-formation ability of cancer cells on 
GOF p53, a phenomenon described as oncogene addiction (18). 
The selective growth advantage of cancer cells harboring GOF 
p53 mutation and the requirement for the continued expression 
of GOF p53 mutants to maintain tumor growth therefore argue 
that cancer cells expressing GOF p53 alleles are indeed depen-
dent on GOF p53 protein, which therefore can be targeted ther-
apeutically in cancer.
How GOF p53 induces oncogenic cell proliferation or why 
the proliferation of cancer cells might be addicted to GOF p53 is 
unknown. Loss of WT p53 and expression of GOF p53 are both known 
to deregulate the cell cycle and to induce untimely S phase entry 
(5), yet GOF p53 also specifically confers a selective proliferation 
advantage. To determine the mechanism of GOF p53–dependent 
growth of cancer cells, we investigated the architecture of genome 
duplication in the presence and absence of GOF p53. Since GOF p53 
mutation is prevalent in lung cancer, human lung cancer or primary 
mouse lung cells were used for these experiments. Our data indicate 
that, in comparison with p53-null, p53-depleted, or loss-of-function 
(non-GOF) p53-expressing cells, lung cells with GOF p53 show a 
higher frequency of origin firing at early S phase, promoting rapid 
genome duplication with errors, as demonstrated by early entry into 
mitosis and increase in micronuclei formation. Consistent with its 
increased origin-firing activity, GOF p53 increased expression of the 
intra–S phase checkpoint kinase CHK1, known to prevent collapse 
of replication forks. Thus, in comparison with p53–/– cells, cells with 
GOF p53 show higher levels of CHK1 and phosphorylated CHK1 and 
reduced frequency of replication fork collapse. In contrast, p53–/– or 
p53-depleted cells show decreased origin firing, higher frequen-
cy of replication fork collapse, and increased levels of chromatin- 
associated histone H2AX (γH2AX). Compromise of GOF p53–medi-
ated transcriptional activation abrogated its ability to increase origin 
firing, form micronuclei, and activate the intra–S phase checkpoint, 
reestablishing replication fork collapse and reduced cell prolifera-
tion. Genome-wide analyses revealed that GOF p53 recognizes the 
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cancer cells with GOF p53 mutation. These data provide com-
pelling evidence that GOF p53 establishes oncogene addiction in 
cancer cells by generating and fostering DNA replication forks and 
that inactivation of these functions of GOF p53 may represent a 
promising therapeutic avenue in cancer.
Results
GOF p53 mutation and loss of WT p53 hasten time of S phase entry to 
a similar extent. While loss of p53 deregulates the cell cycle to enter 
S phase (5), several laboratories have demonstrated that GOF p53 
accelerates cell proliferation and tumor growth in comparison 
promoters of genes encoding cyclin A (CCNA2), needed for origin 
firing (19–21), and CHK1, needed for preventing collapse of repli-
cation forks (22–24), and activates their expression in a cell cycle–
dependent manner at the level of transcription.
Collapse of replication forks is known to induce either cell 
death or gross chromosomal rearrangement due to incomplete 
DNA replication (25, 26). Consistently, experiments utilizing a 
mouse xenograft model revealed that inhibition of CHK1 reduced 
the size of tumors generated from a human lung cancer cell line 
with GOF p53 mutation more efficiently than GOF p53 knock-
down cells and selectively reduced proliferation of cultured lung 
Figure 1. Compared with p53-null or p53-depleted cells, transformed or nontransformed lung cells harboring GOF p53 fire more DNA replication origins 
at early S phase. Fiber images (A) display bidirectional origin and elongating or terminating forks. Percentages of origins in replicating fibers from lung 
cells of p53–/–, p53R172H-KI (R172H), and WT (p53WT) mice (B) and mock-depleted (shGFP) or p53-depleted (shp53) lung cancer cell lines H1048 (D), 
which harbors R273C, and VMRC, which harbors R175H (F), are shown by bar graphs. Expression of p53 was determined by immunoblot analysis in each 
experiment (C, E, G). WT p53 expression (C) was visualized by analyzing higher protein (6-fold over p53R172HKI lung cell extract) and longer exposure. Actin 
is a loading control. Lung cells from 2 mice of each construct or 2 clones stably expressing shGFP or shp53 were analyzed. The P values calculated using 
Student’s t test are shown at the bottom of the bar graphs. Additional fiber images are shown in Supplemental Figures 2 and 3. Each experiment was 
repeated 3 times, and representative data are shown.
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to incorporate the nucleotide analogue iodode-
oxyuridine (IdU) was determined at various times 
after replating by immunostaining IdU and scor-
ing IdU-labeled cells using confocal microscopy. 
The data showed that lung cells from p53-null and 
p53R172H-KI mice entered S phase at similar times, 
with 20% to 23% cells incorporating IdU at 12 hours 
after replating density-arrested cells, while lung 
cells from normal (WTp53) mice showed 5% to 7% 
IdU-labeled cells under similar conditions (Supple-
mental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/
JCI87724DS1). These data suggest that the absence 
of p53 or presence of p53R172H hastens S phase 
entry to a similar extent.
Compared with p53-null cells, the frequency of 
DNA replication origin firing is higher in cells express-
ing GOF p53 mutants. Since GOF p53 mutants acti-
vate expression of genes required for DNA replica-
tion (27), the ability of these mutants to increase 
firing of DNA replication origins during S phase 
entry was determined. To determine whether GOF 
p53 mutants alter frequency of DNA replication ori-
gin firing in otherwise normal cells, lung cells from 
p53–/– and p53R172H-KI mice were cultured and the 
frequency of origin firing during early S phase was 
determined using fiber analysis of replicating DNA using meth-
ods published earlier (28–30). Cells were partially synchronized 
by density arrest and replating and sequentially labeled with IdU 
and chlorodeoxyuridine (CldU) at early S phase. Cellular genomic 
DNA was then spread on slides, and replicating DNA fibers were 
detected by immunostaining of incorporated IdU and CldU using 
with p53-null or -knockdown cells (15, 16) and upregulates expres-
sion of cell-proliferating genes (27). Therefore, experiments were 
carried out to determine whether GOF p53 hastens the time of S 
phase entry compared with p53-null cells. Short-term cultures of 
lung cells from p53R172H-KI (human R175H) and p53-null mice 
were partially synchronized by density arrest, and their ability 
Figure 2. GOF p53 activates intra–S phase checkpoint, pre-
venting collapse of replication forks. Detection of p-CHK1, 
CHK1, and chromatin-associated γH2AX by immunoblot 
analysis using (A) lung cells of p53–/– and p53R172H-KI 
(R172H) mice and (C) mock-depleted (shGFP) or p53- 
depleted (shp53) H1048 lung cancer cells. For detection of 
chromatin-associated γH2AX, insoluble chromatin fraction 
was acid extracted and analyzed by immunoblotting. Band 
intensities of γH2AX normalized by H3 levels are shown 
by bar graphs (B and D). Lung cells from 2 mice of each 
construct or 2 clones stably expressing shGFP or shp53 
were analyzed. The experimental strategy for detection 
of replication fork collapse by fiber analysis is shown by a 
schematic (E). Collapse of progressing replication forks was 
assayed by fiber analysis of replicating DNA. The bar graph 
(F) compares the percentage of red-only tracks (indicated 
by arrows in the fiber images) in replicating fibers. Approxi-
mately 200 untangled fibers from each sample were scored. 
The P value calculated using Student’s t test is indicated 
at the bottom of the bar graph (F). Lung cells from 2 mice 
of each construct were analyzed. Chromatin-associated 
γH2AX levels in lung cells from p53–/– and R172H mice after 
treatment with a CHK1 inhibitor, PF477736, were deter-
mined by immunoblot analysis (G). γH2AX band intensities 
normalized by H3 levels are shown by bar graphs (H). p-RPA 
(Ser4/Ser8) was detected by immunoblot analysis (G) to 
ensure activity of PF477736. Each experiment was repeated 
3 times, and representative data are shown.
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Since GOF p53 accelerates origin firing at early S phase, its ability 
to activate intra–S phase checkpoint for preventing collapse of rep-
lication forks in cells harboring the mutation was investigated. For 
this purpose, lung cells from p53-null and p53R172H-KI mice were 
partially synchronized by density arrest and replating and the cell 
extracts were analyzed for CHK1 expression and phosphorylation 
at S345 by immunoblot analysis. Results (Figure 2A) of these exper-
iments revealed that in comparison with lung cells from p53–/– mice, 
lung cells from p53R172H-KI mice showed higher levels of phos-
phorylated CHK1 (p-CHK1) (9- to 10-fold) and CHK1 (2- to 3-fold) 
at early S phase in repeated experiments, suggesting that GOF p53 
may increase CHK1 phosphorylation during increased origin firing 
by upregulating CHK1 expression.
Since GOF p53 increases CHK1 and p-CHK1 levels, the oncop-
rotein may reduce replication fork collapse and therefore γH2AX 
foci formation. The presence of chromatin-associated γH2AX in 
lung cells from p53-null and p53R172H-KI mice was determined 
by acid extraction of γH2AX from the chromatin fractions and 
immunoblot analysis. The result of this experiment showed that, 
compared with lung cells from p53-null mice, chromatin-asso-
ciated γH2AX levels in lung cells from p53R172H-KI mice were 
drastically reduced (Figure 2, A and B). Similar analysis using 
mock-depleted or p53-depleted H1048 human lung cancer cells 
stably expressing nontargeting shGFP or shp53 showed reduc-
tions in p-CHK1 and CHK1 levels and increases (approximate-
ly 2- to 6-fold) in γH2AX levels in shp53-expressing H1048 cells 
compared with H1048 cells expressing shGFP (Figure 2, C and 
D). These results indicate that expression of GOF p53 increases 
p-CHK1 and CHK1 levels and reduces chromatin-bound γH2AX 
levels, signifying that checkpoint activation by GOF p53 prevents 
collapse of replication forks and thus γH2AX foci formation.
Next, the ability of GOF p53 to reduce frequency of replication 
fork collapse was tested. For this purpose, partially synchronized 
lung cells from p53-null and p53R172H-KI mice were sequentially 
labeled for 20 minutes with IdU and 20 minutes with CldU at early 
S phase. Replicating fibers and direction of fork progression were 
red and green fluorescence–tagged antibodies, respectively, fol-
lowed by confocal microscopy. Scoring of bidirectional origins in 
untangled immunostained DNA fibers (Supplemental Figure 2, A 
and B) revealed that the frequency of origin firing in lung cells from 
p53R172H-KI mice was at least double of that in lung cells from 
p53-null mice (Figure 1, A–C), whereas frequency of origin firing 
in replicating lung cells isolated from normal mice (WT p53) was 
approximately 3-fold lower than that in p53-null mice (Figure 1B) 
as expected. These results suggest that the presence of the GOF 
p53 mutant R172H in nontransformed lung cells accelerates the 
frequency of origin firing at early S phase.
Knockdown of GOF p53 mutant in human lung cancer cells reduc-
es the frequency of origin firing. The ability of GOF p53 mutants to 
increase origin firing in a human lung cancer cell line that natu-
rally expresses GOF p53 was also determined. For this purpose, 
endogenous p53R273C expression in the human SCLC lung can-
cer cell line H1048 or R175H expression in the human non-small 
cell lung cancer (NSCLC) VMRC-LCD cell line (http://p53.iarc.fr/
CellLines.aspx) was stably knocked down by expressing shRNA 
against p53 (shp53) or a control shRNA against GFP (shGFP) from 
a lentiviral expression vector (16). H1048 and VMRC cells stably 
expressing shGFP or shp53 were synchronized by density arrest 
and replating. Fiber analysis of replicating DNA from these cells 
was performed as described above. Scoring of bidirectional ori-
gins in untangled immunostained DNA fibers showed that knock-
down of endogenous p53 significantly reduced frequency of origin 
firing in both the cell lines (Figure 1, D–G). These results indicate 
that GOF p53 mutants accelerate firing of DNA replication origins 
at early S phase in cells harboring p53 mutation.
GOF p53 upregulates expression of intra–S phase checkpoint kinase 
CHK1, preventing collapse of replication forks. Hyperreplicative activ-
ities of oncogenes induce cellular checkpoint responses (31, 32) to 
prevent collapse of progressing replication forks and thus cell death 
(22, 24, 33, 34). Intra–S phase CHK1 is known to protect replica-
tion forks, while inactivation of CHK1 leads to fork collapse, which 
could be evidenced by phosphorylation of γH2AX (22, 24, 33). 
Figure 3. GOF p53 promotes rapid genome duplication and mitotic entry. Percentages of S phase (A) and actively DNA-replicating (B) lung cells generated 
from p53-null and p53R172H-KI mice and their frequency of mitotic entry (C) at 12 and 16 hours after density arrest and replating are shown by bar graphs. 
S phase and DNA-replicating cells were identified by PI staining or BrdU pulse labeling and PI staining followed by flow cytometry. Gating is shown in 
Supplemental Figure 4. Mitotic cells were identified by immunostaining microtubules with FITC-labeled α-tubulin antibody and staining DNA with DAPI 
followed by confocal microscopy (images shown in Supplemental Figure 5). Approximately 500 cells were counted in each sample. The P value calculated 
using Student’s t test is shown at the bottom of the bar graph. Each experiment was repeated 3 times, and representative data are shown.
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of genome duplication and cell proliferation sooner than p53-null 
cells. Thus, the ability of GOF p53 to upregulate CHK1 expression, 
and therefore its activity, may contribute to its ability to confer an 
addictive influence to the cells expressing the mutant protein.
GOF p53 promotes rapid genome duplication and mitotic entry. 
Increased number of origin firing and successful progression of 
generated replication forks should lead to rapid genome dupli-
cation. Therefore, we determined whether GOF p53 promotes 
quicker genome duplication in comparison with p53-null cells by 
analyzing S phase progression and mitotic entry of partially syn-
chronized lung cells from p53-null and p53R172H-KI mice gener-
ated as described above. Flow cytometric analysis of propidium 
iodide–stained (PI-stained) cells at 12 and 16 hours after release 
from density arrest showed that lung cells from both p53R172H-KI 
and p53-null mice entered S phase at a similar time and frequency, 
with approximately 29% of p53R172H-KI and 21% of p53-null cells 
in the S phase at 12 hours after release. However, with progress 
detected in these cells by immunostaining IdU and CldU with red 
and green fluorescence–tagged antibodies, respectively. It was 
reasoned that if the progressing forks collapse during the incorpo-
ration of IdU, these forks should not incorporate CldU and, there-
fore, the red-only tracks should indicate collapse of progressing 
replication forks (Figure 2E). Untangled replicating DNA fibers 
were scored for the presence of red-only tracks. Results of this 
experiment revealed that, in comparison with lung cells from p53-
null mice, the frequency of red-only tracks was drastically reduced 
in lung cells from p53R172H-KI mice (Figure 2, E and F), indicat-
ing a reduction in fork collapse in lung cells expressing p53R172H.
Reduction of replication fork collapse due to activation of 
CHK1 expression by GOF p53 should reduce chromatin associ-
ation of γH2AX. To complete the analysis of GOF p53–mediated 
modulation of fork collapse, this possibility was examined. For 
this experiment, cultured lung cells from p53R172H-KI mice 
were treated with a CHK1 inhibitor, PF00477736. Chromatin- 
associated γH2AX was extracted and analyzed by immunoblot 
analysis. Results of this experiment indicated that the CHK1 
inhibitor PF00477736 elevated the levels of chromatin-associated 
γH2AX more than 6-fold (Figure 2, G and H) as opposed to a 1.6-
fold increase in p53-null lung cells. Consistent with earlier stud-
ies (35, 36), inhibition of CHK1 upregulated RPA phosphorylation 
(at Ser4 and Ser8) due to generation of replication stress (Figure 
2G). These data indicate that GOF p53–mediated reduction in 
γH2AX can be overridden by inhibition of CHK1. These observa-
tions signify that cell proliferation induced by GOF p53 is at least 
partly due to its ability to increase expression of CHK1, the activity 
of which prevents collapse of an increased number of replication 
forks generated by the mutant protein, allowing rapid completion 
Figure 4. Lung cells with GOF p53 form micronuclei at a higher frequency than lung cells from p53-null mice. Representative images of micronuclei 
(indicated by arrows) from lung cells of p53–/– and p53 R 172H-KI (R172H) mice (A) and mock-depleted (shGFP) or p53-depleted (shp53) H1048 lung cancer 
cells (C), detected by confocal microscopy after DAPI staining. Original magnification, ×40. Bar graphs (B and D) compare the percentages of cells with 
micronuclei in each sample. Lung cells from 2 mice of each construct or 2 clones stably expressing shGFP or shp53 were analyzed. Five hundred cells were 
scored for each sample. P values calculated using the χ2 test are shown at the bottom of the bar graphs. Each experiment was repeated twice, and repre-
sentative data are shown.
Table 1. An inhibitor of origin firing reduces micronuclei 
formation in lung cells of p53R172H-KI mice
Mouse number Treatment Nuclei with micronuclei 
(500 scored)
55 DMSO 36
PHA76749 (6 μM) 25
67 DMSO 39
PHA76749 (6 μM) 27
P = 0.0014249.
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through S phase, at 16 hours, lung cells from p53-null mice accu-
mulated in S phase (43.5%), whereas lung cells from p53R172H-
KI mice progressed to G2/M, showing 29.6% S phase cells (Figure 
3A). Accordingly, at 16 hours, 23.7% of p53R172H-KI cells com-
pleted genome duplication and entered G2/M phase as opposed 
to 15.3% of lung cells from p53-null mice (Supplemental Figure 
4, A–D). These data were further confirmed by identifying repli-
cating cells at 12 and 16 hours after release from density arrest by 
pulse labeling with BrdU followed by PI staining. Flow cytometric 
analysis (Supplemental Figure 4, E and F) showed that, consistent 
with the data shown in Figure 3A, similar percentages of lung cells 
from p53R172H-KI or p53-null mice incorporated BrdU (18.8% 
and 16%, respectively) at 12 hours. However, at 16 hours, 28.5% of 
p53-null cells incorporated BrdU, most (90%) of which remained 
in early or mid–S phase. In contrast, only 10.8% of lung cells from 
p53R172H-KI mice were found in early and mid–S phase (Figure 
3B). Next, mitotic entry of the lung cells at 16 hours after release of 
density-arrested cells was determined. Mitotic cells (Supplemen-
tal Figure 5) were identified by immunostaining microtubules with 
α-tubulin antibody and staining nuclei with DAPI. Percentages of 
cells in mitosis were determined by scoring 500 cells for mitot-
ic nuclei under a fluorescent microscope. The results revealed 
that lung cells from p53R172H-KI mice entered mitosis at a 2.5- 
to 2.8-fold higher frequency than did p53-null lung cells (Figure 
3C). These results show that p53-null lung cells take longer times 
to complete genome duplication to enter mitosis compared with 
p53R172H-KI lung cells, which complete genome duplication and 
enter mitosis sooner than p53-null lung cells.
GOF p53 induces micronuclei formation, which can be prevented 
by blocking origin firing. Increased frequency of origin firing has 
been implicated in genomic abnormality (22, 24, 37–40), and one 
of the indicators of genomic abnormality is micronuclei forma-
tion (41–43). Although an increase in CHK1 levels would protect 
collapse of replication forks stalled due to increased origin firing, 
it has been reported that the topological stress associated with 
progress of an increased number of replication forks may lead to 
genome abnormality by mechanisms such as fork reversal, which 
could be evidenced by micronuclei formation (39, 40). Since GOF 
Figure 5. The transactivation function of GOF p53 is required for cell proliferation, increased frequency of replication origin firing, micronuclei forma-
tion, CHK1 expression and phosphorylation, and replication fork protection. (A) Schematic showing functional domains of p53, including its TADI and 
TADII, sites of hot spot mutations, and created mutations on TADI (L22Q and W23S) and TADII (L53Q and F54S). Reg, regulatory. (B) Rate of proliferation 
of H1299 cells stably expressing p53R273H or its TADI mutant was determined. Data are presented as mean ± SD of triplicate experiments. Two clones 
of TADI mutants were used. (C) p53 expression was confirmed by immunoblot analysis. (D) Origin firing was determined by fiber analysis of replicating 
DNA. Data obtained by scoring 200 untangled fibers are shown by a bar graph. P value calculated using Student’s t test is shown at the bottom of the 
graph. (E) Micronuclei formation was determined by DAPI staining. Data obtained by scoring 500 cells are shown by bar graphs. P value calculated using 
χ2 test is shown at the bottom of the bar graphs. (F) Expression of CHK1 and p-CHK1 (at S345) in H1299 cells expressing p53R273H or its TADI mutant was 
determined by immunoblot analysis. (G) γH2AX foci formation in H1299 cells expressing p53R273H or TADI mutant was determined by immunostaining 
with Alexa Fluor 488–coupled γH2AX antibody followed by confocal microscopy. Arrows indicate nuclei with green foci. Original magnification: ×20. (H) 
Frequency of nuclei with γH2AX foci in each construct is shown by bar graph; 250 cells were scored, and P value was calculated using Student’s t test.  
Each experiment was repeated 3 times.
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p53 increases origin firing, the frequency of micronuclei formation 
in the presence or absence of GOF p53 was determined. For this 
purpose, cultured lung cells generated from p53-null or p53R172H-
KI mice were plated on coverslips, fixed and stained with DAPI, 
and cells with micronuclei were scored by confocal microscopy. 
Scoring of cell nuclei associated with micronuclei revealed that 
lung cells from p53R172H-KI mice formed micronuclei at a signifi-
cantly higher frequency than lung cells from p53-null mice (Figure 
4, A and B). Furthermore, it was determined whether knockdown 
of p53 reduces micronuclei formation in human lung cancer cells. 
H1048 cells (p53R273C) expressing shGFP or shp53 were cultured 
on coverslips, fixed and stained with DAPI, and scored for cells 
with micronuclei. Results of this experiment revealed a signifi-
cant reduction in the frequency of cells generating micronuclei in 
H1048 cells stably expressing shp53 compared with those express-
ing shGFP (Figure 4, C and D). These data indicate that GOF p53 
increases micronuclei formation, an index of genetic abnormality.
Next, experiments were designed to determine whether increas-
es in the frequency of origin firing elevate micronuclei formation 
by GOF p53. It is known that in mammalian cells, DNA replication 
origins are activated by cyclin-dependent kinases (CDK) and CDC7 
kinase, which induces melting of double-stranded DNA at the origin 
of replication (44, 45). Since GOF p53 induces origin firing, a CDC7 
kinase inhibitor, PHA767491, which specifically prevents activation 
of origins but does not prevent fork progression (46, 47), was used 
to determine whether inhibition of origin firing in lung cells harbor-
ing a GOF p53 mutation would reduce frequency of micronuclei 
formation. Lung cells from p53R172H-KI mice were treated with 
PHA76749 or vehicle (DMSO) for 3 replication cycles (approximate-
ly 72 hours), and the frequency of micronuclei formation was deter-
mined as described above. The results (Table 1) of this experiment 
showed reduction in percentages of nuclei associated with micro-
nuclei in lung cells from p53R172H-KI mice. These data indicate 
that inhibition of origin firing in lung cells from p53R172H-KI mice 
reduces their ability to generate micronuclei.
The transactivation function of GOF p53 mutants is required for 
GOF p53’s ability to accelerate cell growth, increase firing of DNA 
replication origins, form micronuclei, and protect replication forks. 
GOF p53 mutants activate transcription of growth-promoting 
genes using GOF p53’s transactivation domains (TADs) (Figure 
5A; refs. 12, 13, 48, 49). The transactivation function of GOF p53 
mutants has been related to the ability of GOF p53 to induce tum-
origenesis and cell proliferation (50, 51). Therefore, experiments 
were designed to investigate whether the transactivation function 
of GOF p53 is also required for its ability to increase cell growth, 
origin firing, micronuclei formation, and CHK1 expression and to 
reduce γH2AX foci formation. For this purpose, plasmids express-
ing p53R273H or p53R273H with compromising mutations (Fig-
Figure 6. GOF p53 upregulates expression of an array of genes involved in regulation of cell cycle and DNA replication and localizes on their upstream 
regulatory sequences. Heat maps of transcripts generated from RNA-Seq analysis (A) and DNA fragments generated from ChIP-Seq analysis (B) of H1299 
cells stably transfected with vector (Vector) and stably expressing p53R273H (R273H). Number of sequences identified in B was too numerous to be listed 
in the figure. Gray areas indicate no p53 binding. A Venn diagram (C) shows 121 genes common between the RNA-Seq and ChIP-Seq gene list, representing 
81.75% of the RNA-Seq genes and 69.54% of the p53 ChIP-Seq genes that are involved in cell cycle and DNA replication. Genes that showed greater than 
2-fold upregulation by expression of the p53R273H mutant and whose P value was less than 0.01 were considered significant.
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ure 5D). This observation indicates that to induce origin firing, 
p53R273H requires its transactivation function.
The ability of the transactivation-deficient p53R273HTADI 
or TADI/TADII mutants to induce micronuclei formation was 
determined by staining of fixed cells on coverslips with DAPI and 
scoring cells with micronuclei by confocal microscopy. The results 
revealed that H1299 cells expressing transactivation-deficient 
p53R273HTADI or TADI/TADII formed micronuclei less fre-
quently than H1299 cells expressing transactivation-competent 
p53R273H (Figure 5E). Consistently, transactivation-deficient 
p53R273HTADI did not activate expression and phosphorylation 
ure 5A) of TADI (L22Q, W23S) or TADI and TADII (L22Q, W23S, 
L53Q, F54S) were stably introduced into p53-null H1299 human 
lung cancer cells, and the ability of the stable transfectants to per-
form the above biological activities was determined. Examination 
of the rate of cell proliferation revealed that H1299 cells expressing 
p53R273H proliferated more rapidly than cells expressing either 
empty vectors or TADI mutants of p53R273H (Figure 5, B and C). 
Fiber analysis of replicating DNA from H1299 cells expressing 
p53R273H, p53R273HTADI, or p53R273HTADI/TADII at ear-
ly S phases showed that H1299 cells expressing p53R273H fired 
almost 3-fold more origins than either of the TAD mutants (Fig-
Figure 7. GOF p53 localizes on the upstream sequences of CCNA2 and CHK1 genes. The peaks represent areas under which maximal p53R273H binding 
occurs, as apparent by next-generation sequence analysis of ChIP fragments. Peaks of ChIP fragments on CCNA2 promoter from H1299 cells stably trans-
fected with control vector (A) or stably expressing p53R273H (B). ChIP analysis (C) to confirm localization of p53R273H on CCNA2 promoter. Peaks of ChIP 
fragments on CHK1 promoter from H1299 cells stably transfected with control vector (D) or stably expressing p53R273H (E). ChIP analysis (F) to confirm 
localization of p53R273H on CHK1 promoter. Results from triplicate sets of extracts of H1299 cells expressing p53R273H (273H) or empty vector are shown 
by bar graphs as mean ± SEM. ChIP using IgG control (IgG) has been included in each case. The region of genome showing p53R273H-specific binding 
as determined by ChIP and the direction of coding sequences are indicated by arrows. Blue and purple arrowheads indicate Myc- and E2F-binding sites, 
respectively, on the identified promoter sequences.
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lapse, the profile of genes activated by GOF p53 mutant R273H was 
determined by RNA-Seq analysis. RNA was extracted from H1299 
cells stably expressing p53R273H or stably transfected with empty 
vector, and the expression profiles were compared. To determine the 
mechanism by which GOF p53 mutants increase origin firing and 
prevent collapse of replication forks, profiles of genes involved in the 
regulation of DNA replication were analyzed. The analysis revealed 
that, indeed, GOF p53 mutants upregulated an array of genes that 
regulate cell cycle and DNA replication (Figure 6A).
GOF p53 mutants recognize regulatory elements upstream of cell 
cycle and DNA replication genes. To determine whether GOF p53 
mutants localize on the regulatory elements of the DNA replica-
tion genes, ChIP using H1299 cells stably expressing p53R273H 
was performed. Chromatin fragments bound to p53R273H were 
of CHK1 (Figure 5F). Immunostaining of γH2AX foci showed a 
drastic increase in foci formation in H1299 cells expressing trans-
activation-deficient p53R273H TADI mutants compared with 
H1299 cells expressing p53R273H (Figure 5, G and H). These 
results indicate that the ability of GOF p53 mutants to accelerate 
cell proliferation, increase origin firing and micronuclei forma-
tion, upregulate expression and phosphorylation of CHK1, and 
protect fork collapse requires its transactivation function.
GOF p53 mutants upregulate expression of genes involved in cell cycle 
regulation and DNA replication. Several laboratories have demon-
strated that GOF p53 accelerates cell proliferation and tumor growth 
in comparison with p53-null or GOF p53–knockdown cells (12, 15, 
16). Since the data presented above indicate that GOF p53 requires 
its TADs to increase origin firing and to prevent replication fork col-
Figure 8. GOF p53 induces cyclin A and CHK1 expression. Transcript levels of cyclin A and CHK1 in lung cells from p53-null or R172H-KI (R172H) mice (A and 
B) and H1048 human lung cancer cells stably expressing shRNA against GFP or p53 (F and G), determined by RT-QPCR. Data are plotted as mean ± SEM. 
Cyclin A and CHK1 protein levels (C–E and H–J) were determined by immunoblot analysis. Bar graphs show band intensities of cyclin A (D and I) and CHK1 (E 
and J) determined by densitometry and normalized by ERK2 loading control. Lung cells from 2 mice of each construct or 2 clones stably expressing shGFP 
or shp53 were analyzed. Each experiment was repeated 3 times.
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mental Figure 6). These results strongly support the hypothesis 
that p53R273H activates expression of DNA replication genes by 
targeting their regulatory sequences.
GOF p53 mutants recognize upstream regulatory sequences of 
CCNA2 and CHK1 transcription start sites. The ChIP-Seq analysis 
described above detected localization of p53R273H on the upstream 
sequences of the CCNA2 and CHK1 genes, expression of which are 
needed for firing of DNA replication origins (19–21) and stability of 
initiated replication forks (22–24), respectively. Therefore, experi-
ments were performed to confirm localization of p53R273H on the 
upstream regulatory sequences of these genes. ChIP analysis (Fig-
ure 7) showed that an anti-p53 antibody immunoprecipitated DNA 
fragments spanning a 335-bp region 106 bp upstream of the CCNA2 
transcription start site (Figure 7, A–C) and a 1000-bp region 200 bp 
upstream of the CHK1 transcription start site (Figure 7, D–F). These 
data show that p53R273H localizes on the upstream sequences of 
the CCNA2 and CHK1 transcription start sites.
pulled down using 2 p53 antibodies, DO1 and FL393. Pulled 
down fragments were analyzed by ChIP-Seq. H1299 cells stably 
transfected with vector and IgG isotypes of the antibodies were 
used as controls. Four to ten million reads obtained from Illu-
mina HiSeq were analyzed using the ArrayStar 11 (DNASTAR) 
program. The analysis revealed that p53R273H localizes on the 
upstream regulatory sequences of an array of genes involved in 
cell cycle regulation and DNA replication (Figure 6B). A Venn 
diagram (Figure 6C) shows that there are 121 genes in common 
between RNA-Seq and p53 ChIP-Seq data, representing 81.75% 
of the genes detected by RNA-Seq and 69.54% of the genes 
detected by p53 ChIP-Seq that are involved in cell cycle and 
DNA replication, 2 of which are cyclin A and CHK1. Localization 
of p53R273H on the regulatory regions of some of the replica-
tion genes identified by ChIP-Seq and their activated expression 
detected by RNA-Seq were confirmed by ChIP and quantitative 
reverse-transcriptase PCR (RT-QPCR), respectively (Supple-
Figure 9. A small molecule inhibitor of CHK1 selectively inhibits growth and reduces tumor size of lung cancer cells with p53 mutation. Rate of proliferation 
of (A) H1299 cells stably expressing p53R273H or its TADI mutant or a vector control; (B) proliferation of H1299 cells stably expressing p53 mutants 281GΔ100–
300, 267P, 175H, and 281G; and (C) H1048 lung cancer cells stably expressing shp53 or shGFP in the presence of a CHK1 inhibitor PF00477736 (100 nM) (Inhibi-
tor) or only solvent (DMSO). Data are shown as mean ± SD from triplicate experiments. Rate of tumor growth (D and E) from H1048 cells expressing shGFP or 
shp53 treated with vehicle or PF00477736, 10 mg per kg (drug). Data from 2 sets of clones (D and E) and representative photographs (F) of tumors are shown. 
Representative data from n = 4 mice in each experimental group are plotted as mean ± SEM. Assay was repeated in n = 12 mice per experimental group.
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and G) and protein levels (Figure 8, H–J). Consistently, in a simi-
lar experiment, knockdown of p53R175H in VMRC human lung 
cancer cells also reduced localization of GOF p53 on CCNA2 and 
CHK1 promoters and expression of cyclin A and CHK1 transcript 
and protein levels (Supplemental Figure 7). Taken together, these 
results show that GOF p53 mutants increase cyclin A and CHK1 
expression at early S phase and that inactivation of this function 
abrogates cell proliferation, increase in origin firing, micronuclei 
formation, CHK1 activation, and chromatin association of γH2AX.
p53 Mutants with compromised tumor formation ability do not 
show localization on CCNA2 or CHK1 promoter, do not upregulate 
cyclin A and CHK1 promoter to increase expression of respective 
transcripts, and fire fewer origins than GOF p53 mutants. GOF p53 
mutations often show allele specificity. To determine wheth-
er the ability of GOF p53 mutants to localize on the CCNA2 or 
CHK1 promoter, upregulate expression of cyclin A and CHK1, 
and increase origin firing relates to its tumor formation ability, 
we chose a naturally occurring p53 mutant, R267P, in human 
lung cancer cell line H1437. Tumor-formation ability of the 
H1437 cell line is not dependent on R267P (15). In addition, we 
tested a deletion mutant of GOF p53, D281G Δ100–300, that 
removes its central DNA binding domain (residues 100–300) 
and thus removes the site of hot spot mutation. ChIP analysis 
using p53-null H1299 lung cancer cells stably expressing empty 
vector, p53 D281G Δ100–300, R267P, R175H, R248W, or D281G 
as described above showed that, as in the case of H1299 cells sta-
bly expressing R273H (Figure 7), anti-p53 antibodies immuno-
precipitated upstream promoter fragments of CCNA2 and CHK1 
GOF p53 mutants activate expression of cyclin A and CHK1 at ear-
ly S phase. Since RNA-Seq data (Figure 6A) presented above suggest 
that GOF p53 increases cyclin A and CHK1 expression and GOF p53 
recognizes their upstream regulatory sequences (Figure 7), exper-
iments were performed to confirm whether GOF p53 upregulates 
cyclin A and CHK1 expression at early S phase in the absence of oth-
er known gene mutations. Cell cycle–dependent expression of cyclin 
A and CHK1 in partially synchronized lung cells from p53-null and 
p53R172H-KI mice at early S phase were compared. RT-QPCR of 
transcripts and immunoblot analysis of extracts prepared from these 
cells showed a significant increase in cyclin A and CHK1 expres-
sion at the RNA (Figure 8, A and B, respectively) and protein levels 
(Figure 8, C–E) in lung cells from p53R172H-KI mice in comparison 
with lung cells from p53-null mice. These data are consistent with 
the immunoblot analysis (Figure 2A), which showed that lung cells 
from p53R172H-KI mice express higher levels of CHK1 in compari-
son with lung cells from p53-null mice, suggesting that an increase in 
CHK1 expression leads to an increase in p-CHK1.
Knockdown of GOF p53 diminishes cyclin A and CHK1 expression 
at early S phase in a human lung cancer cell line. To further confirm 
whether GOF p53 increases cyclin A and CHK1 expression at early S 
phase, GOF p53 was knocked down in H1048 lung cancer cell lines. 
H1048 cells stably expressing control shGFP or shp53 RNA were 
partially synchronized by confluence arrest and replating. Expres-
sion of cyclin A and CHK1 was analyzed at early S phase. RT-QPCR 
of transcripts and immunoblot analysis of cell extracts prepared 
from these cells showed that knockdown of GOF p53 significant-
ly reduced cyclin A and CHK1 expression at the RNA (Figure 8, F 
Figure 10. GOF p53 promotes inaccurate genome duplication, whereas p53-null cells show collapse of replication forks. The downstream consequences 
of unscheduled origin firing in (A) GOF p53–expressing and (B) p53-null lung cells are depicted.
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the sensitivity of the human lung cancer cell line H1048 to the 
CHK1 inhibitor (Figure 9C). These observations indicate that the 
growth of H1299 cells expressing GOF p53 mutants is dependent 
on CHK1 induction by GOF p53 and signify potential therapeutic 
efficiency of the CHK1 inhibitor in lung cancer cells expressing 
GOF p53 alleles.
To determine whether the CHK1 inhibitor preferentially 
targets cells that proliferate faster independently of GOF p53, 
we boosted cell proliferation by enriching growth media using 
20% FBS and compared the efficiency of growth inhibition of 
mock-depleted and p53-depleted H1048 lung cancer cells or of 
vector-transfected H1299 cells with GOF p53 R273H–expressing 
H1299 cells in normal media by the CHK1 inhibitor PF00477736. 
Our data (Supplemental Figure 10) show that the enriched media 
increased cell growth in the presence or absence of CHK1 inhib-
itor. Although growth acceleration of p53-depleted H1048 cells 
was higher in the absence of CHK1 inhibitor compared with its 
presence, mock-depleted H1048 cells showed more sensitivity 
to CHK1 inhibitor in normal or enriched media (Supplemental 
Figure 10A). Enhanced proliferation of H1299 lung cancer cells 
(vector control) in enriched media did not increase efficiency of 
growth inhibition by CHK1 inhibitor (Supplemental Figure 10B). 
These data suggest that the efficiency of inhibition of cell growth 
by CHK1 inhibitor is not dependent on rate of proliferation alone.
If an increase in CHK1 expression, and therefore replication 
fork protection, renders cancer cells addicted to p53, inhibition 
of CHK1 should also reduce tumor growth. This possibility was 
examined using a mouse xenograft model. Subcutaneous tumors 
were allowed to form in immunodeficient Nu/Nu mice (Nu/Nu 
mice) by introducing H1048 cells stably expressing shGFP or 
shp53, and the effect of CHK1 inhibitor PF00477736 on tumor 
growth was examined. H1048 cells expressing shGFP efficient-
ly formed tumors, while PF-00477736 treatment significantly 
reduced the size of the tumors (Figure 9, D–F). Knockdown of 
p53R273C with shp53 also efficiently reduced tumor size; how-
ever, PF-00477736 treatment did not reduce the size of the 
H1048shp53 tumors appreciably. Comparing the effect on H1048 
shGFP and shp53 cells, PF-00477736 reduced size of tumors gen-
erated from H1048shGFP cells at 3.6- to 4-fold higher efficiency 
than that from H1048 shp53 cells (Supplemental Figure 11, B and 
C). These data indicate that tumors expressing GOF p53 are tar-
geted efficiently and selectively by PF 00477736 in comparison 
with tumors not expressing GOF p53.
Discussion
Targeting GOF p53 mutants to prevent tumor growth or to treat 
established tumors has recently become an area of active inves-
tigation predicated on reversing the apparent addiction of tumor 
cells to the GOF properties of mutant p53 (13, 17, 18). However, 
why or how growth of tumors or tumor cells becomes dependent 
on GOF p53 is not known.
The tumorigenic activity of GOF p53 and its ability to transcrip-
tionally activate genes required for DNA replication (27, 50–52) 
drew the focus of this study on firing of DNA replication origins and 
progression of replication forks, the 2 crucial aspects of success-
ful genome duplication. Consistent with the reports in literature 
(53–55), the presented ChIP-Seq and RNA-Seq analyses (Figure 6 
from cells expressing p53 mutants R175H, R248W, or D281G, but 
not from cells expressing empty vector, p53 D281G Δ100–300, 
or R267P (Supplemental Figure 8, A and B).
Next, we analyzed the abilities of the p53 mutants to upreg-
ulate CCNA2 and CHK1 promoter activities. CCNA2 and CHK1 
promoters containing the GOF p53–interaction sites as deter-
mined from our ChIP analysis (Figure 7) were inserted upstream 
of a luciferase gene in a reporter plasmid. The plasmids were 
introduced in p53-null H1299 cells along with the individual p53 
mutants or vector plasmid, and luciferase activity was deter-
mined as reported earlier (16). Our data (Supplemental Figure 9, 
A–C) show that expression of GOF p53 mutants R175H, R248W, 
R273H, or D281G upregulated luciferase activity compared with 
empty vector or compared with the mutants p53 D281G Δ100–
300 or R267P. RT-QPCR of transcripts and immunoblot analysis 
of extracts prepared from partially synchronized H1299 cells sta-
bly expressing the p53 mutants showed that, consistent with the 
promoter activity, R175H, R248W, R273H, or D281G significantly 
increased cyclin A and CHK1 transcript and protein levels com-
pared with empty vector or compared with the mutants p53 D281G 
Δ100–300 or R267P (Supplemental Figure 9, D–H). Fiber analysis 
of replicating DNA from H1299 stable transfectants expressing 
the p53 mutants D281G Δ100–300, R267P, R175H, and 281G at 
early S phase showed that H1299 cells expressing R175H and 281G 
fired almost 3- to 4-fold more origins than cells expressing either 
D281G Δ100–300 or R267P (Supplemental Figure 9I). These 
results show that GOF p53 mutants localize on the CCNA2 and 
CHK1 promoter sequences, increase CCNA2 and CHK1 promoter 
activities and their expression, and increase origin firing at early S 
phase, whereas p53 mutants deficient in GOF properties are inac-
tive in these functions.
A small molecule inhibitor of CHK1 selectively reduces tumor 
size and growth of lung cancer cells with p53 mutation. If increased 
expression of CHK1 by GOF p53 protects replication fork progres-
sion (Figure 2) and thus accelerates genome duplication (Figure 3) 
and cell proliferation (Figure 5B), GOF p53–mediated cell prolifer-
ation should be selectively prevented by inhibition of CHK1 activ-
ity. To test this possibility, H1299 lung cancer cells stably express-
ing p53R273H or its transactivation-deficient mutant p53R273H 
TADI (Figure 5A) and H1299 cells stably transfected with vec-
tor control were treated with a CHK1 inhibitor, PF00477736, 
and the rate of cell proliferation was determined. The results of 
these experiments show that PF00477736 preferentially inhib-
ited growth of cells expressing GOF p53R273H compared with 
p53R273H TADI or cells expressing vector control (Figure 9A and 
Supplemental Figure 7A). In a similar experiment, H1299 cells 
expressing p53 mutants D281G Δ100–300, R267P, R175H, and 
281G were treated with PF00477736 and cell number at 5 days 
was determined. Consistent with the previous finding, results 
(Figure 9B) of this experiment show that PF00477736 inhibited 
growth of H1299 cells expressing p53R175H or p53D281G more 
efficiently than cells expressing D281G Δ100–300 or  R267P. Simi-
larly, H1048 lung cancer cells (which naturally express p53R273C) 
stably expressing shRNA against p53 or control GFP were also 
treated with the CHK1 inhibitor, and rate of cell proliferation was 
determined by counting cell numbers in each case. Our data show 
that knockdown of GOF p53 remarkably reduced (2.5- to 3-fold) 
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by topological stress due to increase in origin firing as reported by 
Neelsen et al. (39). In support of this notion, reduced micronuclei 
formation was observed in the presence of a CDK2 inhibitor that is 
known to inhibit origin firing but allow fork progression (Table 1).
Supporting the central role of GOF p53–mediated transacti-
vation of CHK1 in preventing collapse of replication forks, it was 
observed that a CHK1 inhibitor (Figure 2, G and H) or inhibition of 
CHK1 expression by transcriptional inactivation of GOF p53 leads 
to collapse of replication forks (Figure 5G). It is known that the col-
lapse of replication forks leads to either cell death or gross genom-
ic rearrangement due to incomplete genome duplication (25, 26). 
GOF p53–mediated fork stabilization, therefore, should allow the 
cells to evade these events detrimental to cell growth, although the 
cells enter S phase as early as p53-null cells. Accordingly, a CHK1 
inhibitor preferentially inhibited proliferation of cells and growth 
of tumors expressing GOF p53 (Figure 9 and Supplemental Figure 
11), while transactivation-deficient GOF p53 with substitution at 
the amino acid residues 22 and 23 was incapable of increasing 
origin firing, micronuclei formation, replication fork stabilization 
and induction of cell proliferation (Figure 5), and vulnerability to 
CHK1 inhibitor (Figure 9, A and B), implicating GOF p53 transacti-
vation in regulating all these functions. Consistently, p53 mutants 
deficient in GOF property did not transactivate CCNA2 and CHK1 
or increase origin firing and were not vulnerable to the CHK1 
inhibitor (Supplemental Figure 9 and Figure 9B).
These results help explain the genetic instability and long 
latency period of tumorigenesis found in p53-null cells (61). 
Higher incidence of replication fork collapse and gross genome 
rearrangement in p53-null cells should lead to cell death, but also 
selection of genetically altered cells with survival advantage and 
tumorigenesis in the long run. GOF p53–driven increases in ori-
gin firing along with protection of replication forks should allow 
proliferation of cells with genetic abnormalities. These observa-
tions also explain dependence of tumor growth on GOF p53, lack 
of which would result in decreased origin firing and vulnerability 
to collapse of progressing replication forks, causing decelerated 
rates of genome duplication and lethal genome rearrangement. 
Our model for the role of GOF p53 in stimulating replication 
and simultaneously protecting replication forks (Figure 10) pro-
vides solid mechanistic justification for developing cancer cell– 
selective therapeutics that target either GOF p53 transactivation 
function directly or target the protein products of GOF p53–trans-
activated genes. Such therapies, possibly in combination with oth-
er tumor type–specific targeted therapies, may lead to therapeutic 
gains in intractable cancers with high rates of GOF p53 mutation.
Methods
Plasmids, lentiviral vectors, and cell lines. Generation of plasmids, len-
tiviruses, and stable transfectants expressing GOF p53 or shRNA 
against GFP or p53 was carried out using pLKO.1 expression vector 
purchased from Open Biosystem following the supplier’s protocols. 
Lung cells from mice were generated and cultured following standard 
protocols (28, 62). CCNA2 promoter was a gift from Toshio Nikaido 
(63). CHK1 promoter was constructed by isolating upstream promoter 
regions by PCR using primer sequences listed in Supplemental Table 
1. H1299 and H1048 cell lines were obtained from ATCC. The VMRC-
LCD cell line was obtained from JCRB Cell Bank.
and Supplemental Figure 6) indicate that GOF p53 recognizes the 
promoter region of several genes involved in DNA replication and 
upregulates their expression, suggesting that the oncoprotein cre-
ates an intracellular environment conducive to accelerated genome 
duplication. Here, we present data to suggest what we believe is a 
novel oncogenic pathway (Figure 10, A and B), in which GOF p53–
dependent growth advantage of cancer cells lies in its ability to 
localize on the upstream regulatory sequences of CCNA2 and CHK1 
(Figure 7 and Supplemental Figure 8), upregulating their expression 
(Figure 8 and Supplemental Figures 7 and 9). Since more origins 
are licensed than used (reviewed in refs. 36, 56), increase in cyclin 
A expression leads to firing of more origins of replication (Figure 1 
and Supplemental Figure 9F), whereas increased CHK1 expression 
prevents their collapse (Figure 2), thus quickening genome duplica-
tion (Figure 3) and proliferation of cells with genetic abnormalities, 
as evidenced by micronuclei formation (Figure 4 and Figure 5E). 
In contrast, due to their inability to upregulate cyclin A and CHK1 
expression, p53-null cells or cells expressing GOF-deficient p53 
mutants activate fewer origins than cells with GOF p53 (Figure 1) 
and face a vulnerability to collapse of replication forks (Figure 2), 
which is known to cause incomplete genome duplication, gross 
genome rearrangement, and cell death (25, 26).
Cell cycle progression is deregulated in the absence of WT p53, 
which normally induces expression of the CDK inhibitor p21 (57). 
Consistently, data presented here show that lung cells from either 
p53-null or p53R172H-KI mice enter S phase at similar times, 
with approximately 20% of the cells synthesizing DNA at early S 
phase while approximately 5% of lung cells from mice with WT 
p53 enter S phase at a similar time (Supplemental Figure 1). Thus, 
the presence of GOF p53 does not hasten time of S phase entry any 
sooner than loss of p53 (Supplemental Figure 1). However, expres-
sion analysis did reveal that at early S phase, GOF p53 upregulates 
expression of cyclin A, required for origin activation, and CHK1, 
required for stabilization of replication forks (Figure 8 and Supple-
mental Figures 7–9) and, accordingly, increases the frequency of 
origin firing (Figure 1 and Supplemental Figure 9F) and prevents 
collapse of progressing replication forks (Figure 2), accelerating 
genome duplication and cell growth (Figure 3 and Figure 5B).
Oncogene-induced replication stress is thought to induce fir-
ing of dormant origins, which facilitates completion of genome 
duplication (58). However, the observed increase in origin firing 
by GOF p53 was concomitant to S phase entry of cells and was 
dependent on TADI of GOF p53, needed to upregulate cyclin A 
expression (Figure 5D). Since activation of CDK activates origins 
in replication factories (59, 60), GOF p53–induced cyclin A expres-
sion at early S phase should activate origin firing in replication fac-
tories. Increases in the levels of p-CHK1 in GOF p53–expressing 
cells (Figure 2, A and B) may eventually fire dormant origins due to 
pausing of progressing replication forks at a later time point.
Our data also show that the increase in the frequency of ori-
gin firing by GOF p53 led to micronuclei formation in lung cells 
expressing GOF p53 (Figure 4). It has been reported that onco-
gene-induced increase in DNA replication induces fork reversal 
and generates unfinished replication intermediates (39). Although 
activation of CHK1 by GOF p53 prevents fork collapse, micro-
nuclei formation in GOF p53–expressing cells may possibly be a 
consequence of mitotic processing of the intermediates generated 
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minutes) and blocking (2% BSA in PBS), DNA fibers on slides were 
immunostained with primary antibodies against IdU and CIdU fol-
lowed by fluorescently labeled secondary and tertiary antibodies, 
washed, dried, and mounted in ProLong Gold Antifade (Life Tech-
nologies). Images were collected by confocal microscopy (Zeiss 
LSM700). Newly initiated single origins were detected as red track 
flanked on both sides by green track as explained in the legend of 
Figure 4A. Approximately 150 to 200 fibers from each sample were 
scored and analyzed using ImageJ software (NIH).
Cell cycle analysis and detection of mitotic nuclei. Cell cycle analy-
sis was performed by ethanol fixation and PI staining at different time 
intervals after replating density-arrested cells and flow cytometry (BD 
FACSCanto II). Cell cycle analysis was performed using BD FACSDi-
va software. For identification of mitotic nuclei, density-arrested cells 
were replated on coverslips and fixed using 3% paraformaldehyde. 
The cells were then treated with 0.1% Triton X-100 for 10 minutes, 
followed by PBS washes and 1 hour blocking in 5% BSA. The primary 
antibody incubation was performed in the blocking buffer for 1 hour 
followed by PBS wash and 1 hour incubation with Alexa Fluor 488–
conjugated secondary antibody. Cells were briefly stained with DAPI 
solution, washed, mounted on slides using ProLong Gold Antifade, and 
imaged by confocal microscopy (Zeiss LSM700) at ×40 magnification.
Detection of micronuclei. Cultured cells were plated on coverslips 
and fixed using 3% paraformaldehyde, mounted on slides with Pro-
Long Gold Antifade with DAPI, and imaged using confocal micro-
scopy (Zeiss LSM700). Presence of micronuclei was examined for 
500 randomly selected cells.
Detection of γH2AX. Cultured cells were washed with PBS and har-
vested. The cell pellet was digested in lysis buffer (10 mM HEPES, pH 7.9, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1.5 mM PMSF) containing 0.2 
N HCl for 30 minutes. The supernatant was neutralized with phosphate 
buffer. Chromatin-bound γH2AX was detected by immunoblot analysis. 
For detection of γH2AX foci, cultured cells were plated on coverslips and 
fixed using 3% paraformaldehyde. The cells were then treated with 0.1% 
Triton X-100 for 10 minutes, followed by PBS washes and 1 hour block-
ing in 5% BSA. The primary antibody incubation was performed in the 
blocking buffer for 1 hour followed by PBS wash and 1 hour incubation 
with Alexa Fluor 488–conjugated secondary antibody. Coverslips were 
mounted on slides using ProLong Gold Anitfade with DAPI and imaged 
by confocal microscopy (Zeiss LSM700) at ×40 magnification; 250 cells 
were randomly examined for presence of γH2AX.
Immunoblot analysis and quantification. Immunoblot analysis was 
performed following standard techniques. Antibodies are described 
above. Quantitative comparisons were performed using Quantity One 
4.6.2 software (Bio-Rad).
RNA extraction and sequencing. Total RNA was isolated from expo-
nentially growing cultured cell lines using TRIzol reagent (Life Tech-
nologies) following the supplier’s protocols. For RNA-Seq, 4 μg of total 
RNA was processed and sequenced at Donnelly Sequencing Center at 
the University of Toronto (Toronto, Canada). RNA samples were run on 
the Illumina HiSeq 2500 System, and individual fastq files were used 
for analysis. Sequences were aligned to the human genome (HG19) 
and analyzed using DNASTAR ArrayStar (version 12) software. All 
RNA-Seq experiments were normalized by assigned reads per kilobase 
of template per million (RPKM) mapped reads. RNA-sequencing infor-
mation can be found in the ArrayExpress database (accession umber: 
E-MTAB-5652). For more information, see Supplemental Table 2.
Animals. p53-Null and p53R172H KI mice were generated by 
crossbreeding corresponding heterozygous (p53+/– and p53R172H/
WTp53, respectively) mice (gifts from Guillermina Lozanom, refs. 64, 
65). Nude mice were obtained from Jackson Laboratory.
Chemicals and drugs. IdU and CldU were purchased from Sigma- 
Aldrich. PHA767491 (Tocris Bioscience) was used at a concentration 
of 10 μM for indicated times (46, 47). CHK1 inhibitor PF-00477736 
(Sigma- Aldrich) was used at a concentration of 50 nM for 24 hours for 
treatment of cultured cells and 10 mg per kg for treatment of tumors (35).
Antibodies. Antibodies used included anti-p53 (catalog sc-6243), 
CHK1 (catalog sc-56288), cyclin A (catalog sc-751), ERK-2 (catalog 
sc-154), and actin (catalog sc-47778) (Santa-Cruz Biotechnology Inc.); 
phospho CHK1 (catalog 2348s) (Cell Signaling Technology); γ-H2AX 
(catalog 05-636), and H3 (catalog 1953330) (Millipore). Antibodies 
were used per the manufacturer’s protocol. Mitotic cells were identified 
by staining with α-tubulin antibody (T9026) (Sigma-Aldrich). Anti- 
human p53 monoclonal antibody was a gift from David Lane (Agency 
for Science, Technology and Research, p53 Laboratory, Singapore). IdU 
was detected by mouse anti-bromodeoxyuridine (347580) from BD 
primary antibody and Alexa Fluor 594–conjugated rabbit anti-mouse 
and Alexa Fluor 594–conjugated goat anti-rabbit (Life Technologies) 
secondary and tertiary antibodies, respectively. CldU was detected by 
rat anti-bromodeoxyuridine (OBT0030G) primary antibody (Accurate) 
and Alexa Fluor 488–conjugated chicken anti-rat and Alexa Fluor 488–
conjugated goat anti-chicken (Life Technologies) secondary antibodies.
Detection of replicating nuclei. Replicating nuclei were detected 
following methods described earlier (28). Briefly, density-arrested 
cells were replated on coverslips and labeled with 40 μM IdU for 20 
minutes at desired times after replating. IdU was washed off using 
PBS. Cells were fixed with 3% paraformaldehyde solution. Fixed cells 
were treated for 5 minutes with 0.5% Triton X-100, followed by 1 hour 
treatment with 2.5 N HCl to denature the DNA, and neutralized with 
3 washes of 0.1 M sodium borate. Cells were then washed with 0.1% 
Tween in PBS (wash buffer) and blocked in 2% BSA in wash buffer for 
an hour. The cells were then sequentially incubated with primary and 
Alexa Fluor 594–conjugated secondary antibodies each for an hour in 
1% BSA in wash buffer. The coverslips were washed and mounted on 
slides with ProLong Gold Antifade with DAPI (Life Technologies) and 
imaged using confocal microscopy (Zeiss LSM700).
Detection of replicating cells by flow cytometry. Flow cytometric 
analysis of replicating cells was performed using methods described 
earlier (66, 67). Cells were labeled with nucleotide analogue BrdU as 
described above. For flow cytometry, cells were fixed with 70% etha-
nol at 4°C overnight. Acid base treatment and immunostaining were 
conducted using the protocol described above using an Alexa Flu-
or 488–conjugated anti-BrdU antibody (BD Biosciences). DNA was 
stained with PI. The samples were analyzed using a BD FACScanto II 
flow cytometer using BD FACSDiva software.
Identification of DNA replication origin firing. DNA replication 
origin firing was determined by DNA fiber spreading analysis follow-
ing published protocols (28–30, 68). Briefly, cells were pulse labeled 
sequentially with nucleotide analogues IdU (40 μM) and CIdU (100 
μM) to track the replication pattern and directionality of fork move-
ment. Cells were collected by trypsinization, and genomic DNA of 
approximately 600 cells was aligned on slides by fiber spreading as 
described earlier. Slides were then air dried, fixed in 3:1 methanol/
acetic acid, and dried overnight. After acid treatment (2.5N HCl, 30 
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ously in both flanks and measured periodically following published pro-
tocols (70). The H1048 cell line expressing shRNA against p53 or GFP 
was used. Tumor size was assessed at day 10, and mice were equally 
distributed into 2 groups to receive daily 10 mg/kg of PF-0047773 dis-
solved in 2% DMSO, 40% PEG, or vehicle by intraperitoneal injection.
Statistics. Unless otherwise specified, all experiments were per-
formed in triplicate and representative data are shown. The pres-
ence of bidirectional origins as well as collapsed forks detected by 
sequential labeling of replicating DNA in different samples in each 
experiment set were compared using Student’s t test. Percentages of 
mitotic cells between different samples were compared using Stu-
dent’s t test. Micronuclei per cell for different samples were evalu-
ated using the χ2 test. QPCR reactions were performed in duplicate 
and repeated in 3 independent experiments. All immunoblots were 
repeated 3 times, and representative data are shown. Unless other-
wise specified, for all the experiments, a P value of less than 0.05 was 
considered significant.
Study approval. All animal studies were approved by the Institu-
tional Animal Care and Use Committee (IACUC) at the Virginia Com-
monwealth University.
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ChIP analysis and sequencing. ChIP and ChIP-Seq were performed 
using standard methods (69). Briefly, exponentially growing H1299 
cells expressing either empty vector or the p53 mutant p53R273H were 
fixed with formaldehyde, extracted, and immunoprecipitated with 
antibodies against p53 (DO1 and FL-393, Santa Cruz Biotechnology 
Inc.). DNA fragments were eluted from immunoprecipitates, reverse 
crosslinked, and purified. Purified DNA (150 ng) was sequenced at the 
Donnelly Sequencing Center at the University of Toronto. ChIP sam-
ples were run on the Illumina HiSeq 2500 System, and individual fastq 
files were used for analysis. Sequences were aligned to the human 
genome (HG19) and analyzed using DNASTAR ArrayStar (version 12) 
software. Peaks were visualized using SeqMan Pro software (DNAS-
TAR). ChIP-Seq experiments were normalized by reads assigned per 
million mapped reads (RPM). Genome sequences that showed bind-
ing of p53 in p53-R273H–expressing cells but no binding in vector cells 
or where there was greater than 1.5-fold higher binding in the p53-
R273H cells were chosen for further analysis. Gene lists for RNA-Seq 
and ChIP-Seq were compared to determine which genes were upregu-
lated by mutant p53 and which also have p53 binding to the promoter.
For ChIP analysis, DNA samples were suspended in water and the 
presence of cyclin A and CHK1 promoter fragments were analyzed by 
3 contiguous sets of primers as listed in Supplemental Table 1.
Generation of cDNA and quantitative PCR. RNA extraction, 
cDNA preparation, and quantitative PCR (QPCR) were performed 
following standard protocols (27). cDNA was synthesized using the 
Thermoscript Reverse Transcription–PCR system (Life Technol-
ogies). QPCR was carried out using a LightCycler system (Roche). 
Primers (Supplemental Table 1) were designed using OLIGO 5 soft-
ware (Molecular Biology Insights) and were synthesized by Inte-
grated DNA Technologies. Reactions were performed in duplicate 
utilizing SYBR green dye, which exhibits a higher fluorescence upon 
binding of double-stranded DNA.
Analysis of CCNA2 and CHK1 promoter activity. H1299 cells were 
transfected with 200 ng of luciferase reporter plasmid (pGL3), with 
luciferase reporter under the control of CCNA2 (63) or CHK1 promoter 
sequences or empty pGL3 basic vector (Promega), and 1 μg of the indi-
cated p53 expression plasmid using Lipofectamine 2000 (Invitrogen) 
following the manufacturer’s instructions. Cell lysates were prepared 
48 hours after transfection, and luciferase activity was determined. 
Luciferase analysis was carried out using the luciferase assay system 
(E1500) and instructions from Promega. Experiments were per-
formed in triplicate as described before (16).
Xenograft studies. Nu/Nu mice were used for the tumorigenicity 
studies. Eight-week-old mice were injected with 1 × 107 cells subcutane-
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